person · Reporting owner

Legault Pierre

Disclosed activity across 6 companies

Tapewire entity: 67394
SEC CIK: 0001391045

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Adynxx, Inc.ADYX · Entity 155807	Director	May 03, 2019	May 07, 2019
BICYCLE THERAPEUTICS PLCBCYC · Entity 5993	Director	January 02, 2025	January 06, 2025
Syndax Pharmaceuticals IncSNDX · Entity 4578	Director	February 04, 2026	February 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Adynxx, Inc.

Report date May 03, 2019 · Filed May 07, 2019

This filing explicitly reported no securities owned.

BICYCLE THERAPEUTICS PLC

Report date January 02, 2025 · Filed January 06, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	46,000	Reported balance After 2025-01-02 transaction · row 1 1 source row Row 1 · 2025-01-02 · Grant · Acquired 12,500 · Balance 46,000 F1: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. F2: Each RSU represents a contingent right to receive one ordinary share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2035-01-02	Direct	25,000	Reported balance After 2025-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-01-02 · Grant · Acquired 25,000 · Balance 25,000 F3: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025.

F2: Each RSU represents a contingent right to receive one ordinary share.

F3: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025.

Syndax Pharmaceuticals Inc

Report date February 04, 2026 · Filed February 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	114,000	Reported balance After 2026-02-04 transaction · row 1 1 source row Row 1 · 2026-02-04 · Grant · Acquired 24,000 · Balance 114,000 F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Filing footnotes · ownership attribution and instrument terms

F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARMO BioSciences, Inc.

Report date March 26, 2018 · Filed June 22, 2018

Section 16 reporting ended · disclosed 2018-06-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.97 · Expires 2028-03-25	Direct	0	Reported balance After 2018-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-22 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.73 · Expires 2027-05-31	Direct	0	Reported balance After 2018-06-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-06-22 · Disposition to issuer · Disposed 55,765 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F4: This option, which provided for vesting in forty-eight equal monthly installments following April 18, 2017, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share.

F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.

F3: This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

F4: This option, which provided for vesting in forty-eight equal monthly installments following April 18, 2017, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.

Tobira Therapeutics, Inc.

Report date November 01, 2016 · Filed November 03, 2016

Section 16 reporting ended · disclosed 2016-11-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.83 · Expires 2023-11-17	Direct	Reported balance After 2016-11-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-11-01 · Disposition to issuer · Disposed 6,111 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.93 · Expires 2023-12-31	Direct	Reported balance After 2016-11-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-11-01 · Disposition to issuer · Disposed 535 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.52 · Expires 2025-07-08	Direct	Reported balance After 2016-11-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-11-01 · Disposition to issuer · Disposed 15,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.91 · Expires 2026-01-12	Direct	Reported balance After 2016-11-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-11-01 · Disposition to issuer · Disposed 17,778 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.19 · Expires 2025-01-01	Direct	Reported balance After 2016-11-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-11-01 · Disposition to issuer · Disposed 17,695 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time") F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"), F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor. F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. ("Parent") and Sapphire Acquisition Corp. ("Purchaser"), pursuant to which Purchaser was merged with and into Issuer (the "Merger"), each option to purchase shares (a "Company Option") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the "Shares") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the "Closing Amount") (each, an "In the Money Option"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the "Effective Time")

F2: (continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an "Out of the Money Option"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement ("CVR Agreement") on or prior to the fifth anniversary of the Effective Time (each such date, a "Valuation Point"),

F3: (continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor.

F4: The Shares subject to this option were fully vested immediately prior to the Effective Time.

Urovant Sciences Ltd.

Report date March 29, 2021 · Filed March 31, 2021

Section 16 reporting ended · disclosed 2021-03-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-03-29 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-03-29 · Disposition to issuer · Disposed 12,480 · Balance 0 F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-03-29 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2021-03-29 · Disposition to issuer · Disposed 9,000 · Balance 0 F2: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.53 · Expires 2028-06-09	Direct	Reported balance After 2021-03-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-03-29 · Disposition to issuer · Disposed 13,350 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.01 · Expires 2028-11-21	Direct	Reported balance After 2021-03-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-03-29 · Disposition to issuer · Disposed 36,650 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2029-07-09	Direct	Reported balance After 2021-03-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-03-29 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2030-07-21	Direct	Reported balance After 2021-03-29 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-03-29 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the consummation of the Merger, each outstanding common share of the Issuer ("Common Share") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

F2: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

F3: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 04, 2026 Filed Feb 6, 2026 16:06 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantCommon Stock	24,000	$0.00	$0.00	Disclosure SEC source: 0001193125-26-041167 · ownership.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document
February 05, 2025 Filed Feb 7, 2025 16:32 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0000950170-25-016346 · ownership.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document
January 02, 2025 Filed Jan 6, 2025 19:30 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0001415889-25-000929 · form4-01062025_070130.xml · derivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. Read SEC document
January 02, 2025 Filed Jan 6, 2025 19:30 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantOrdinary Shares	12,500	$0.00	$0.00	Disclosure SEC source: 0001415889-25-000929 · form4-01062025_070130.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,000 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document
February 07, 2024 Filed Feb 9, 2024 16:04 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantCommon Stock	17,000	$0.00	$0.00	Disclosure SEC source: 0001562180-24-001214 · primarydocument.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document
January 02, 2024 Filed Jan 4, 2024 18:35 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (right to buy) · Derivative	24,000	$0.00 Strike: $18.08	$0.00	Disclosure SEC source: 0001209191-24-000889 · doc4.xml · derivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Ordinary Shares · 24,000 shares Expires 2034-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024. Read SEC document
January 02, 2024 Filed Jan 4, 2024 18:35 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantOrdinary Shares	12,000	$0.00	$0.00	Disclosure SEC source: 0001209191-24-000889 · doc4.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,500 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document
February 02, 2023 Filed Feb 3, 2023 16:54 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantCommon Stock	16,000	$0.00	$0.00	Disclosure SEC source: 0001562180-23-000944 · primarydocument.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document
January 13, 2023 Filed Jan 13, 2023 16:44 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	5,000	$0.00 Strike: $13.58	$0.00	Disclosure SEC source: 0001562180-23-000413 · primarydocument.xml · derivative · entry 9 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document
January 13, 2023 Filed Jan 13, 2023 16:44 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	10,000	$0.00 Strike: $13.58	$0.00	Disclosure SEC source: 0001562180-23-000413 · primarydocument.xml · derivative · entry 8 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document
January 13, 2023 Filed Jan 13, 2023 16:44 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	5,000	$27.00	$135,000.00	Disclosure SEC source: 0001562180-23-000413 · primarydocument.xml · nonDerivative · entry 6 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of no options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. Read SEC document
January 13, 2023 Filed Jan 13, 2023 16:44 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	5,000	$13.58	$67,900.00	Disclosure SEC source: 0001562180-23-000413 · primarydocument.xml · nonDerivative · entry 5 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 13, 2023 Filed Jan 13, 2023 16:44 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	10,000	$27.00	$270,000.00	Disclosure SEC source: 0001562180-23-000413 · primarydocument.xml · nonDerivative · entry 4 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of no options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. Read SEC document
January 13, 2023 Filed Jan 13, 2023 16:44 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	10,000	$13.58	$135,800.00	Disclosure SEC source: 0001562180-23-000413 · primarydocument.xml · nonDerivative · entry 3 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 12, 2023 Filed Jan 13, 2023 16:44 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	24,000	$0.00 Strike: $9.47	$0.00	Disclosure SEC source: 0001562180-23-000413 · primarydocument.xml · derivative · entry 7 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2030-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document
January 12, 2023 Filed Jan 13, 2023 16:44 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	24,000	$26.74	$641,781.60	Disclosure SEC source: 0001562180-23-000413 · primarydocument.xml · nonDerivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of no options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $26.50 to $26.93. Read SEC document
January 12, 2023 Filed Jan 13, 2023 16:44 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	24,000	$9.47	$227,280.00	Disclosure SEC source: 0001562180-23-000413 · primarydocument.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:05 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (right to buy) · Derivative	23,000	$0.00 Strike: $29.60	$0.00	Disclosure SEC source: 0001209191-23-002176 · doc4.xml · derivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Ordinary Shares · 23,000 shares Expires 2033-01-03 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2023, June 15, 2023, September 15, 2023 and December 15, 2023. Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:05 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantOrdinary Shares	11,500	$0.00	$0.00	Disclosure SEC source: 0001209191-23-002176 · doc4.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2023, June 15, 2023, September 15, 2023 and December 15, 2023. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document
August 05, 2022 Filed Aug 9, 2022 16:05 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	14,000	$0.00 Strike: $8.93	$0.00	Disclosure SEC source: 0001562180-22-005979 · primarydocument.xml · derivative · entry 6 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2028-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document
August 05, 2022 Filed Aug 9, 2022 16:05 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	10,000	$0.00 Strike: $9.63	$0.00	Disclosure SEC source: 0001562180-22-005979 · primarydocument.xml · derivative · entry 5 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document
August 05, 2022 Filed Aug 9, 2022 16:05 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	14,000	$23.02	$322,222.60	Disclosure SEC source: 0001562180-22-005979 · primarydocument.xml · nonDerivative · entry 4 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 39,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $23.00 to $23.12 Read SEC document
August 05, 2022 Filed Aug 9, 2022 16:05 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	14,000	$8.93	$125,020.00	Disclosure SEC source: 0001562180-22-005979 · primarydocument.xml · nonDerivative · entry 3 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 05, 2022 Filed Aug 9, 2022 16:05 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	10,000	$23.02	$230,159.00	Disclosure SEC source: 0001562180-22-005979 · primarydocument.xml · nonDerivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 39,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $23.00 to $23.12 Read SEC document
August 05, 2022 Filed Aug 9, 2022 16:05 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	10,000	$9.63	$96,300.00	Disclosure SEC source: 0001562180-22-005979 · primarydocument.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 02, 2022 Filed Feb 3, 2022 17:30 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantCommon Stock	16,000	$0.00	$0.00	Disclosure SEC source: 0001562180-22-001073 · primarydocument.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document
January 03, 2022 Filed Jan 5, 2022 17:24 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $60.87	$0.00	Disclosure SEC source: 0001209191-22-001821 · doc4.xml · derivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2032-01-03 F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
January 03, 2022 Filed Jan 5, 2022 17:24 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantOrdinary Shares	10,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-001821 · doc4.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs are fully vested. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document
December 22, 2021 Filed Dec 22, 2021 21:00 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionStock Option (Right to Buy) · Derivative	97,860	$0.00 Strike: $8.48	$0.00	Disclosure SEC source: 0001209191-21-071007 · doc4.xml · derivative · entry 9 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,312 Underlying: Ordinary Shares · 97,860 shares Expires 2029-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.331495 to GBP 1.00 as of December 22, 2021. F8 · derivative.exercise_date: This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022. Read SEC document
December 22, 2021 Filed Dec 22, 2021 21:00 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	SaleOrdinary Shares	97,860	$58.01	$5,676,858.60	Disclosure SEC source: 0001209191-21-071007 · doc4.xml · nonDerivative · entry 6 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.51 to $58.50 inclusive. Read SEC document
December 22, 2021 Filed Dec 22, 2021 21:00 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionOrdinary Shares	97,860	$8.48	$829,852.80	Disclosure SEC source: 0001209191-21-071007 · doc4.xml · nonDerivative · entry 5 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.331495 to GBP 1.00 as of December 22, 2021. Read SEC document
December 22, 2021 Filed Dec 22, 2021 18:25 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	24,000	$0.00 Strike: $7.88	$0.00	Disclosure SEC source: 0001562180-21-007866 · primarydocument.xml · derivative · entry 6 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2029-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document
December 22, 2021 Filed Dec 22, 2021 18:25 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	24,000	$22.01	$528,206.40	Disclosure SEC source: 0001562180-21-007866 · primarydocument.xml · nonDerivative · entry 4 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 63,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F3 · price: The sale prices ranged from $22.00 to $22.02. Read SEC document
December 22, 2021 Filed Dec 22, 2021 18:25 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	24,000	$7.88	$189,120.00	Disclosure SEC source: 0001562180-21-007866 · primarydocument.xml · nonDerivative · entry 3 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 21, 2021 Filed Dec 22, 2021 21:00 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionStock Option (Right to Buy) · Derivative	44,537	$0.00 Strike: $8.44	$0.00	Disclosure SEC source: 0001209191-21-071007 · doc4.xml · derivative · entry 8 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,172 Underlying: Ordinary Shares · 44,537 shares Expires 2029-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.324735 to GBP 1.00 as of December 21, 2021. F8 · derivative.exercise_date: This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022. Read SEC document
December 21, 2021 Filed Dec 22, 2021 21:00 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	SaleOrdinary Shares	44,537	$57.11	$2,543,508.07	Disclosure SEC source: 0001209191-21-071007 · doc4.xml · nonDerivative · entry 4 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.02 to $57.55 inclusive. Read SEC document
December 21, 2021 Filed Dec 22, 2021 21:00 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionOrdinary Shares	44,537	$8.44	$375,892.28	Disclosure SEC source: 0001209191-21-071007 · doc4.xml · nonDerivative · entry 3 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.324735 to GBP 1.00 as of December 21, 2021. Read SEC document
December 20, 2021 Filed Dec 22, 2021 21:00 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionStock Option (Right to Buy) · Derivative	7,603	$0.00 Strike: $8.41	$0.00	Disclosure SEC source: 0001209191-21-071007 · doc4.xml · derivative · entry 7 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,709 Underlying: Ordinary Shares · 7,603 shares Expires 2029-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.319915 to GBP 1.00 as of December 20, 2021. F8 · derivative.exercise_date: This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022. Read SEC document
December 20, 2021 Filed Dec 22, 2021 21:00 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	SaleOrdinary Shares	7,603	$57.02	$433,523.06	Disclosure SEC source: 0001209191-21-071007 · doc4.xml · nonDerivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.00 to $57.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (5) and (7). Read SEC document
December 20, 2021 Filed Dec 22, 2021 21:00 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionOrdinary Shares	7,603	$8.41	$63,941.23	Disclosure SEC source: 0001209191-21-071007 · doc4.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.319915 to GBP 1.00 as of December 20, 2021. Read SEC document
December 20, 2021 Filed Dec 22, 2021 18:25 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	20,000	$0.00 Strike: $7.08	$0.00	Disclosure SEC source: 0001562180-21-007866 · primarydocument.xml · derivative · entry 5 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2027-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document
December 20, 2021 Filed Dec 22, 2021 18:25 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	20,000	$21.01	$420,250.00	Disclosure SEC source: 0001562180-21-007866 · primarydocument.xml · nonDerivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 63,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $21.00 to $21.0238. Read SEC document
December 20, 2021 Filed Dec 22, 2021 18:25 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	20,000	$7.08	$141,600.00	Disclosure SEC source: 0001562180-21-007866 · primarydocument.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 08, 2021 Filed Apr 9, 2021 16:36 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionStock Option (Right to Buy) · Derivative	24,838	$0.00 Strike: $8.74	$0.00	Disclosure SEC source: 0001209191-21-026247 · doc4.xml · derivative · entry 5 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,312 Underlying: Ordinary Shares · 24,838 shares Expires 2029-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022. Read SEC document
April 08, 2021 Filed Apr 9, 2021 16:36 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	SaleOrdinary Shares	239	$32.13	$7,679.07	Disclosure SEC source: 0001209191-21-026247 · doc4.xml · nonDerivative · entry 4 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.09 to $32.16 inclusive. Read SEC document
April 08, 2021 Filed Apr 9, 2021 16:36 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	SaleOrdinary Shares	12,099	$31.40	$379,908.60	Disclosure SEC source: 0001209191-21-026247 · doc4.xml · nonDerivative · entry 3 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239 F2 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4). Read SEC document
April 08, 2021 Filed Apr 9, 2021 16:36 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	SaleOrdinary Shares	12,500	$32.00	$400,000.00	Disclosure SEC source: 0001209191-21-026247 · doc4.xml · nonDerivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,338 F2 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. Read SEC document
April 08, 2021 Filed Apr 9, 2021 16:36 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionOrdinary Shares	24,838	$8.74	$217,084.12	Disclosure SEC source: 0001209191-21-026247 · doc4.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.37265 to GBP 1.00 as of April 8, 2021. Read SEC document
April 05, 2021 Filed Apr 7, 2021 19:22 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	Exercise / conversionStock Option (Right to Buy) · Derivative	162	$0.00 Strike: $8.83	$0.00	Disclosure SEC source: 0001209191-21-025990 · doc4.xml · derivative · entry 3 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,150 Underlying: Ordinary Shares · 162 shares Expires 2029-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.38618 to GBP 1.00 as of April 5, 2021. F3 · derivative.exercise_date: This option shall vest in 36 equal monthly installments and shall be fully vested on March 15, 2022. Read SEC document
April 05, 2021 Filed Apr 7, 2021 19:22 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	SaleOrdinary Shares	162	$31.07	$5,033.34	Disclosure SEC source: 0001209191-21-025990 · doc4.xml · nonDerivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.